Paper8348686
Molecular characterization of angiotensin II--induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts. Critical role of the AT1 receptor subtype.
Sadoshima J and 1 other. Circ Res, 1993. Cited by 1,257 papers, by iCite.
Cite this record
ConductScience Library. Molecular characterization of angiotensin II--induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts. Critical role of the AT1 receptor subtype. Papers, record 8348686. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/8348686
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Molecular characterization of angiotensin II--induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts. Critical role of the AT1 receptor subtype.
- PubMed
Topics13
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Angiotensin II | Major topic |
| Cardiomegaly | Major topic |
| Myocardium | Major topic |
| Receptors, Angiotensin | Major topic |
| Angiotensinogen | |
| Animals | |
| Cells, Cultured | |
| Fibroblasts | |
| Gene Expression Regulation | |
| Genes, fos | |
| Hyperplasia | |
| Rats | |
| Transforming Growth Factor beta |
Source PubMed
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT03219632 | Fimasartan on Hypertensive Cardiac Disease With Left Ventricular Hypertrophy Estimated by ECG | Background |
Source ClinicalTrials.gov
Cited by295
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1,257 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42696246 | Protective Effect of a Polyherbal Formulation (Cardojith) Against Angiotensin II-induced Hypertension and Cardiomyocyte Hypertrophy Via Modulation of Oxidative Stress and MAPK Signalling. | Appl Biochem Biotechnol | 2026 | https://conductscience.org/library/papers/42696246 | PubMed |
| 42639029 | Investigating angiotensin II concentration in modulating Plasmodium falciparum infection and angiotensin receptor activation. | Front Parasitol | 2026 | https://conductscience.org/library/papers/42639029 | PubMed |
| 42076069 | Ex Vivo Buccal Permeability of Nanostructured Lipid Carriers (NLCs) Associated with a Peptide Drug Model. | Pharmaceutics | 2026 | https://conductscience.org/library/papers/42076069 | PubMed |
| 41542600 | Genetic deletion of cytoglobin exacerbates cardiac hypertrophy and inhibits cardiac fibroblast activation independent of changes in blood pressure. | bioRxiv | 2026 | https://conductscience.org/library/papers/41542600 | PubMed |
| 41209135 | The Association of Angiotensin Converting Enzyme and Angiotensinogen Gene Polymorphism With Dilated Cardiomyopathy: A Systematic Review and Meta-Analysis. | Rev Cardiovasc Med | 2025 | https://conductscience.org/library/papers/41209135 | PubMed |
| 40943161 | Beneficial Effects of Chymase Inhibition on Cardiac Diastolic Function and Remodeling Induced by Chronic Angiotensin II Stimulation. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/40943161 | PubMed |
| 40931092 | Heart failure-specific cardiac fibroblasts contribute to cardiac dysfunction via the MYC-CXCL1-CXCR2 axis. | Nat Cardiovasc Res | 2025 | https://conductscience.org/library/papers/40931092 | PubMed |
| 40894880 | Carfilzomib-specific proteasome β5/β2 inhibition drives cardiotoxicity via remodeling of protein homeostasis and the renin-angiotensin-system. | iScience | 2025 | https://conductscience.org/library/papers/40894880 | PubMed |
| 40872727 | The Renin-Angiotensin-Aldosterone System (RAAS): Beyond Cardiovascular Regulation. | Vet Sci | 2025 | https://conductscience.org/library/papers/40872727 | PubMed |
| 40548179 | The Alleviative Effect of Naringin Against Cardiovascular Dysfunction and Remodeling in Hypertensive Rats by Suppressing the Angiotensin II Pathway. | Food Sci Nutr | 2025 | https://conductscience.org/library/papers/40548179 | PubMed |
| 40332211 | Seven Deadly Sins in Hypertension Management: In-Depth Analysis of the Errors on a Journey from Riva-Rocci to Myocardial Fibrosis. | Arq Bras Cardiol | 2025 | https://conductscience.org/library/papers/40332211 | PubMed |
| 40267335 | Angiotensin II-induced cardiac fibrosis and dysfunction are exacerbated by deletion of cGKI in periostin+ myofibroblasts. | Clin Sci (Lond) | 2025 | https://conductscience.org/library/papers/40267335 | PubMed |
| 40028060 | Angiotensin II-Induced Hypertrophy in H9c2 Cells Reveals Severe Cytotoxicity of Graphene Oxide. | ACS Omega | 2025 | https://conductscience.org/library/papers/40028060 | PubMed |
| 39830783 | Advances in Selenium and Related Compounds Inhibiting Multi-Organ Fibrosis. | Drug Des Devel Ther | 2025 | https://conductscience.org/library/papers/39830783 | PubMed |
| 39712736 | Shakuyaku-Kanzo-To Prevents Angiotensin Ⅱ-Induced Cardiac Hypertrophy in Neonatal Rat Ventricular Myocytes. | Cureus | 2024 | https://conductscience.org/library/papers/39712736 | PubMed |
| 39638825 | A multi-omics approach identifies the key role of disorders of sphingolipid metabolism in Ang II-induced hypertensive cardiomyopathy myocardial remodeling. | Sci Rep | 2024 | https://conductscience.org/library/papers/39638825 | PubMed |
| 39475011 | Left atrial function in uraemic patients: Four-dimensional automatic left atrial quantitative technology study. | ESC Heart Fail | 2025 | https://conductscience.org/library/papers/39475011 | PubMed |
| 39452290 | FGFR4 Is Required for Concentric Growth of Cardiac Myocytes during Physiologic Cardiac Hypertrophy. | J Cardiovasc Dev Dis | 2024 | https://conductscience.org/library/papers/39452290 | PubMed |
| 39078503 | Sex-based differences in left ventricular mass reduction across angiotensin II receptor blockers in patients with heart failure with preserved or mildly reduced ejection fraction. | Heart Vessels | 2025 | https://conductscience.org/library/papers/39078503 | PubMed |
| 39076280 | Healing the Ischaemic Heart: A Critical Review of Stem Cell Therapies. | Rev Cardiovasc Med | 2023 | https://conductscience.org/library/papers/39076280 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| AGT | 183 | PubTator's text mining | https://conductscience.org/library/genes/183 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Comments and corrections
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/8348686
GET https://conductscience.org/api/papers/v1/8348686/cited_by?page=2